부산대학교 도서관

Background: Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are both B-cell lymphomas, but MCL is clinically more aggressive and associated with a worse prognosis. The treatment planning and novel targeted agents for these two diseases are also different. Therefore, it is necessary to differentiate between the two promptly and accurately. Method: We collected immunophenotyping data of 28 cases of CLL and MCL by multiparameter flow cytometry. We performed statistical analysis in correlation with pathological diagnosis. Result: In our lab, we combined the lymphoma panel with the newly incorporated CD200 surface marker into our flow cytometry workflow. Based on the characteristics of cell surface antigens in lymphoma, we analyzed the data by logical gating strategy. Among 28 cases we analyzed, there were 10 cases whose pathological sections were stained positive cyclin D1 by immunohistochemistry, pathological diagnoses were MCL and CD200 expressions were negative by flow cytometry. In the other 18 cases, those cyclin D1 were negative, pathological diagnoses were CLL and CD200 expressions were positive. It shows that the concordance rate is 100% between pathological examination and CD200 expression. Furthermore, the flow cytometry is a faster procedure and can produce test results within 5 hours. Conclusion: We will integrate CD200 into our innovative customized lyophilized multiparameter lymphoma panel, simplify the operation steps, and enhance the report output rate. Furthermore, the sampling process is less invasive than the traditional pathological examination, and less affected by the biopsy location. And therefore, we can help physicians make the distinguishing diagnosis of CLL versus MCL more instantaneously.